Abstract
Introduction
Agranulocytosis is a potentially life-threatening hematological condition of acute onset in which the number of circulating neutrophils falls to less than 500/mm 3 (3) (4) (5) 
. Even with the advent of granulocyte colony-stimulating factors and new antibiotics, this disorder leads to an increased risk of bacterial infections and sepsis, resulting in a case-fatality rate of approximately 5-15% (1, 2). Azithromycin (AZM) is a macrolide antibiotic, structurally modified from erythromycin and noted for its activity against some gram-negative organisms particularly Haemophilus influenzae

F i g u r e 1 . Ch a n g e s i n wh i t e b l o o d c e l l c o u n t a n d a b s o l u t e n e u t r o p h i l c o u n t o v e r t i me a d mi n i s t r at i o n s o f a z i t h r o my c i n a n d G-CS F a r e i n d i c a t e d b y ■ a n d ↓ , r e s p e c t i v e l y .
day (day 1) and ANC count recovered to 4,704/mm 3 on day 7. Because all symptoms improved, the patient was discharged. The patient has been well and no recurrence of agranulocytosis was seen.
Discussion
Although clinical studies have demonstrated that AZM has no major or consistent effect on laboratory safety parameters, the incidence of treatment-related abnormalities in blood cell count, particularly leukocyte/neutrophil, has been reported (6) (7) (8) . Higa (9) . Currently, this disorder remains a potential serious adverse event due to the frequency of severe sepsis and septic shock in approximately two-thirds of all hospitalized patients (2, 10) .
In conclusion, we present the first documented case of AZM-related agranulocytosis in an adult patient. Physicians must pay careful attention to identifying drug-induced neutropenia in AZM-treated patients because early detection can decrease the severity and prevent mortality.
